ROS自催化纳米平台可抑制星形胶质细胞与癌细胞的交互作用,进而增强胶质母细胞瘤治疗效果。
ROS-autocatalytic nanoplatform interfering astrocyte-cancer crosstalk and enhancing glioblastoma therapy
Chen Yun, Tian Zonghua, Fan Hongrui, Zhou Jingyi, Zhang Shilin, Li Xuwen, Su Boyu, Jiang Chen, Sun Tao
Journal:Nature Communications
IF:18.1
DOI:10.1038/s41467-026-77395-2
PMID:
Published:2026-09-10
research field:肿瘤学分子生物学遗传筛选药理学癌症生物学信号转导
Abstract
Glioblastoma (GBM) remains incurable and exhibits exceptionally high metabolic demands, driving the evolution of hyperactive mitochondrial systems within tumors. In parallel, mitochondrial transfer from astrocytes to cancer cells fuels metabolic reprogramming and enhances GBM tumorigenicity. These malignant traits markedly constrain therapeutic efficacy and patient survival. Herein, we report a dehydroascorbic acid (DHA)-functionalized, ROS-responsive, ferrocene-integrated polymer nanoplatform (GS@DFP) co-loaded with S-Gboxin and Galunisertib, simultaneously targeting GBM mitochondria and mitochondrial transfer in astrocyte-cancer cell crosstalk. After crossing the blood-brain barrier (BBB) through Glut1-mediated transport enabled by DHA, GS@DFP responds to elevated intracellular reactive oxygen species (ROS) levels in GBM to trigger payload release and initiate Fenton reactions. S-Gboxin inhibits mitochondrial complex V and depletes ATP, whereas Galunisertib downregulates TGF-β/SMAD-driven thrombospondin-1 (TSP-1) expression, suppressing tumor microtube (MT) formation and thereby reducing astrocyte-to-GBM mitochondrial transfer. Notably, TGF-β inhibition also reprograms the immunosuppressive tumor microenvironment (TME). This work establishes a multifunctional nanoplatform that targets mitochondrial vulnerabilities and intercellular crosstalk, offering a translatable strategy for enhancing GBM therapy.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


